Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk

  |  Issue: June 2018  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Regeneron Pharmaceuticals, Inc. News release: Regeneron reports first quarter 2018 financial and operating results. 2018 May 3.
  2. Taylor NP. Regeneron halts high doses of phase 3 osteoarthritis drug fasinumab amid risk-benefit concerns. FierceBiotech. 2018 May 3.
  3. Stein R. FDA panel affirms safety of painkiller celebrex. NPR. 2018 Apr 25.

Related Articles

    Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

    Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…

    Celecoxib Is a Safe Treatment for Arthritis

    A study compared celecoxib with ibuprofen and naproxen to determine its cardiovascular safety, as well as gastrointestinal and renal outcomes, in patients with rheumatoid arthritis and osteoarthritis. The results showed that celecoxib met all prespecified noninferiority requirements and is as safe as other non-selective NSAIDs…